Remote PK/PD Module expert: Translational / Clinical Pharmacology Decision-Maker - AI Trainer ($175-$250 per hour) at Mercor

The client is seeking an external expert who brings a **decision-maker’s mindset** — someone who has personally driven translational pharmacology choices under governance and uncertainty.### **Who we’re looking for** - Has owned FIH starting dose, SAD/MAD design, and Phase 2 dose selection for multiple assets. - Participated in governance or review boards, defending dose/exposure rationale in front of senior leadership or regulators. - Demonstrates ability to balance **nonclinical → clinical translation**: tox, PK, PD, potency, and MoA. - Can articulate the **real decision calculus** behind dose selection (safety, pharmacology, speed-to-proof). - Capable of turning narrative judgment into **explicit decision rules and rubrics** for AI training and evaluation. ### **Experience level** - ~10+ years in major biopharma or biotech (e.g., Lilly, Roche, AbbVie, Amgen, Novartis, GSK, Regeneron, Vertex, Incyte, Gilead) or in specialized translational pharmacology consulting. - Has **personally led** FIH dose and/or SAD/MAD escalation for ≥2–3 assets. - Proven governance experience: IND sign-off, dose justification memos, exposure–response presentations. - CV or track record includes statements like _“led clinical pharmacology strategy and FIH dose selection”_ or _“accountable for exposure–response in Phase 1/2.”_ - Avoid pure modeling profiles; the ideal expert has **decision accountability**, not just analytical skill. ### **Expectations** - Write “golden” FIH dose rationales and escalation strategies for representative programs. - Encode the **decision heuristics and trade-offs** used by senior translational leaders into structured guidance and rubrics. - Surface **unwritten decision rules** — when and why experienced teams override model-based recommendations. **Inputs given:** - Representative drug programs or data packets (GLP tox summaries, PK/PD tables, potency & MoA context). - Target prompts for translational decision-making (e.g., _“Recommend FIH dose and escalation strategy given these data”_). **Expected outputs:** - **Golden Decision Memos:** exemplar dose justification memos that reflect the level of reasoning and format expected from top-tier translational pharmacologists. - **Decision Rubrics:** scoring guides capturing acceptable vs. unsafe dose rationales, missed edge cases, or failure modes. - **Meta-Layer Commentary:** short narrative explaining unspoken heuristics — how senior teams weigh risk tolerance, potency data, or tox uncertainty.